Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Needham Keeps Buy on Rigel Pharmaceuticals


Needham reiterated the buy rating on Rigel Pharmaceuticals (RIGL).

Analyst Mark Monane says positive data results will enable Rigel to move on to late-stage testing and secure a collaborative partnership for its allergy treatment R112 in the near future. He says the data is clinically meaningful and supports his thesis that R112 is a "nonsteroid steroid."

Monane notes the rapid onset of action and effect on nasal congestion seen with R112 are two beneficial effects typically not seen with intranasal steroids. In anticipation of continued positive news flow in the third and fourth quarters, given Rigel's solid fundamentals, he believes the current valuation is very attractive.

Monane sees a $2.58 2004 loss and a $2.75 2005 loss. He has a $33 target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus